secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000950170-24-054478
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics Q1 2024 net loss $10.9M; cash $72.8M; clinical trials on track
--------------------------------------------------------------------------------

- Net loss of $10.9M vs $6.4M in Q1 2023; R&D expense rose to $8.8M from $5.0M.
- Cash, equivalents and marketable securities $72.8M; runway expected into 2026.
- Phase 2a RIVER trial in RCC fully enrolled? all sites activated; topline data expected H2 2024.
- Phase 2b CORAL trial in IPF chronic cough enrolling ~160 pts; topline data H1 2025.
- HAP study 75% enrolled; IND cleared for Phase 1b respiratory physiology trial starting Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000095017024054478/0000950170-24-054478-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000095017024054478/trvi-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-054478

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer